As presented in Table 2, Tempol treatment resulted in a significant reduction in the levels of phosphorylated ERK, JNK, AKT, and mTOR in both gastric cancer cells (CRL-1739-TPL) and colon cancer cells (CC-TPL) when compared to their respective control groups. This evidence concerns the gene AKT1 and gastric cancer.